Publication Details - Overview

View all Online CME

Continuing Education Information

Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Critical Advances in the Management of Immune Thrombocytopenic Purpura

Summaries of Lectures From a Satellite Symposium Held in Conjunction With the 50th ASH Annual Meeting and Exposition
San Francisco, CA
December 6-9, 2008

1 AMA PRA Category 1 Credit(s)™
Release Date: May 23, 2009
Expiration Date: May 23, 2010

Publication Overview

Author

PER Editorial Staff

Overview and Purpose

Immune thrombocytopenic purpura (ITP) is an autoimmune disease characterized by a low platelet count and mucocutaneous bleeding. The low platelet count seen in patients with ITP is the result of accelerated platelet destruction mediated by antiplatelet antibodies and, in some cases, impaired platelet production. The goal of ITP management is to raise and maintain platelet counts in order to prevent life-threatening bleeding events and to improve patient quality of life. Treatment standards for ITP have not changed substantially in > 10 years. Corticosteroids have long been the standard first-line therapy for adults with ITP. Other initial treatment options include intravenous immunoglobulin and anti-D. Splenectomy remains a viable option for patients with refractory ITP, and the anti-CD20 antibody rituximab also has efficacy in this setting. The development of thrombopoietin receptor agonists (TPO-RAs) has provided a new and effective treatment option for the management of patients with refractory ITP.

The purpose of this activity is to update physicians on the treatment of patients with ITP.

Target Audience

This educational activity is intended for medical oncologists and hematologists involved in the care of patients with ITP. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity.

Learning Objectives

Upon completion of this educational activity, you should be able to:

  • Explain how the current understanding of the pathophysiology of ITP led to the development of new targeted therapeutics for patients with ITP
  • Describe the efficacy and safety of initial management options for patients with ITP
  • Evaluate the efficacy and safety of splenectomy in patients with ITP
  • Discuss treatment options for patients with chronic ITP who require acute therapeutic intervention
  • Assess the efficacy and safety of TPO-RAs in the treatment of patients with refractory ITP

Instructions for Participation

  1.  Read the following information before entering the educational activity.
  2. Complete the Pretest.
  3.  Study the educational activity.
  4.  Complete the Posttest.
  5. Answer the evaluation questions.
  6. After completion of the Pretest and successful completion of the Posttest and evaluation, you will receive your certificate online.

You will be permitted 2 attempts to successfully complete the Posttest.

Complete the test(s) and evaluation by May 23, 2010 to receive your certificate online.

Read all of the conditions in the Activity Terms box below. You must accept the CME Activity Terms in order to continue:

Disclosure Policy
It is the policy of Physicians’ Education Resource to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Physicians’ Education Resource has implemented a mechanism to identify and resolve all conflicts of interest prior to the activity.

Satellite Symposium Faculty

Chair:
 Drew Provan, MD
 Senior Lecturer
Department of Haematology
Barts and The London School of Medicine and Dentistry
The Royal London Hospital
London, UK

Faculty:
 Morey Blinder, MD
 Associate Professor
Hematology Division
Department of Medicine
Department of Pathology and Immunology
Washington University School of Medicine
St. Louis, MO

Keith R. McCrae, MD
 Professor of Medicine and Pathology
Case Western Reserve University School of Medicine
Cleveland, OH

Mansoor Saleh, MD
 Director of Research
Georgia Cancer Specialists
Atlanta, GA
Professor of Medicine
UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, AL

PER Editorial Staff
 No relevant relationships to disclose

This CME activity might include discussion of investigational and/or unlabeled uses of drugs. If the activity includes discussion of investigational and/or unlabeled uses of a drug, specific information is located on the title page. Please refer to the full prescribing information for each drug discussed in this activity for FDA-approved dosing, indications, and warnings.

Commercial Support
An educational grant for this activity was provided by Amgen.

Software Requirements
The Web pages and Web-based applications require a minimum Web browser of Microsoft Internet Explorer 5.5 or higher, Mozilla Firefox 1.0 or higher, or another compatible Web browser. If you are not sure of the version of your browser, select Help in the menu bar of your browser, then select About.

PC Users
If you need to upgrade your Web browser, follow one of the links listed below:

Additional software requirements include:

Macintosh Users
Compatible Web browsers include:

Additional software requirements include:

 

Banner Illustration

Illustrator: Pam Curry  

Disclaimer
The views and opinions expressed in this activity are those of the authors and do not necessarily reflect the views of the sponsor, supporter, or publisher. Although great care has been taken in compiling and checking the information given in this activity to ensure accuracy, the authors and Physicians’ Education Resource and its servants or agents shall not be responsible or in any way liable for the continued currency of the information or for any errors, omissions, or inaccuracies in this activity, whether arising from negligence or otherwise howsoever or for any consequences arising therefrom.

Please consult full prescribing information for any drugs or procedures discussed within.

This activity is not sanctioned by, nor a part of, the 50th ASH Annual Meeting and Exposition.

Privacy Policy
Physicians’ Education Resource (PER) makes reasonable efforts to ensure that privacy issues are handled responsibly. PER does not sell or share your information with other organizations that are not directly involved in this process. If you have further concerns, you may contact us at (888) 949-0045.

All rights reserved. No part of this activity may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.

©Copyright 2009 by Physicians’ Education Resource. No material may be reproduced in whole or in part, in any form, without written permission from the publisher.

All correspondence should be directed to:
Editor, Critical Advances in the Management of Immune Thrombocytopenic Purpura
Physicians’ Education Resource
3500 Maple Ave.
Suite 700
Dallas, TX 75219
Phone: (214) 367-3400
Fax: (214) 367-3304
E-mail: editor@cancerlearning.com

Download a Print Version of this Publication*

*Print format is for reference only

Educational Grants

An educational grant for this activity was provided by:


  1. Amgen